Table 1.
Dup15q syndrome participant characteristics
| Age (months) | Gender | Duplication type | Epilepsy (active) | Spike-wave index in sleep | Medications (generic) |
|---|---|---|---|---|---|
| 105 | Female | Isodicentric | No | < 35% |
Risperidone Melatonin |
| 23 | Female | Isodicentric | No | < 35% | None |
| 108 | Female | Isodicentric | No | < 35% | None |
| 18 | Male | Interstitial | No | < 35% | None |
| 35 | Male | Isodicentric | No | < 35% | None |
| 54 | Male | Isodicentric | No | < 35% | None |
| 68 | Female | Isodicentric | Yes | 45–50% |
Clobazam Topiramate |
| 137 | Male | Isodicentric | Yes | 40–45% | Topiramate |
| 73 | Female | Interstitial | Yes | < 35% |
Lamotrigine Guanfacine |
| 19 | Male | Isodicentric | Yes | 35–40% |
Vigabatrin Prednisolone |
| 57 | Female | Isodicentric | Yes | < 35% | None |
| 9 | Female | Isodicentric | Yes | < 35% |
Levetiracetam Phenobarbital |
| 55 | Male | Isodicentric | Yes | 65–70% | None |
| 108 | Male | Isodicentric | Yes | < 35% | None |
| 156 | Male | Isodicentric | Yes | 40–45% | None |
This table describes the characteristics of participants in the Dup15q syndrome cohort. Details on age, gender, epilepsy status and medications were extracted from participant background questionnaires, and duplication type was extracted from participant genetic reports. The percentage of sleep occupied by spike-waves was reported as the spike-wave index in clinical EEG reports and was verified by a board-certified pediatric epileptologist
Dosages were not available for all the medications listed, hence not included in the table